National viral hepatitis control program in India: Call for update

Author:

Pandey Pragya1,Roy Akash2,Bhadoria Ajeet Singh1

Affiliation:

1. Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarkhand, India

2. Department of Hepatology, Institute of Gastrosciences and Liver Transplantation, Apollo Multispeciality Hospitals, Kolkata, West Bengal, India

Abstract

ABSTRACT Viral hepatitis is a serious yet manageable and preventable public health menace that infects about 3 million of people and leads to 1.1 million deaths worldwide every year. An acute episode of viral hepatitis usually subsides on its own, however, if not intervened timely, chronic infection puts people at risk of cirrhosis, liver cancer, and eventually death. In 2015, the global community allied to tackle viral hepatitis, as a result of which combating viral hepatitis target was included in the sustainable development goals (SDGs), and the World Health Organisation (WHO) constituted the first-ever global health sector strategy on viral hepatitis for 2016 to 2021 which is also renewed recently. Conforming to the global commitment, India launched the National Viral Hepatitis Control Program in the year 2018 with the aim to eliminate viral hepatitis as a public health threat by the year 2030. In the Subsequent years, WHO and various other international societies have released updated recommendations with respect to vaccination, prevention of mother-to-child transmission, strategies to increase testing uptake including self-testing, newer diagnostics including point of care and reflex testing approaches, simplified treatment algorithms, expanded treatment eligibility criteria, and simplified service delivery models. With the program being in its fifth year of implementation, there is a need to revamp the operational guidelines based on various global evidence-based advancements in order to attain the ambitious elimination goal by 2030.

Publisher

Medknow

Subject

General Materials Science

Reference11 articles.

1. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection;Balistreri;Hepatology,2017

2. Dual sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection;Yakoot;J Pediatr Gastroenterol Nutr,2018

3. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4;Abdel Ghaffar;J Viral Hepat,2019

4. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic HCV:Part 2 of the DORA study;Jonas;Hepatology,2021

5. Direct-acting antivirals for children with chronic hepatitis C:A Brazilian single center experience;Hirsch;ESPID Meeting 2020:European Society for Paediatric Infectious Diseases,2020

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Epidemiology of Hepatocellular Carcinoma in India – An Updated Review for 2024;Journal of Clinical and Experimental Hepatology;2024-11

2. Response—National viral hepatitis control program in India: Call for update;Journal of Family Medicine and Primary Care;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3